Skip to content

Identification of drug reaction between tuberculosis drugs and other medicines in tuberculosis patients.

Development of prediction model for potential drug-drug interactions between anti-tuberculosis drugs and co-medications among tuberculosis patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/01/048953
Enrollment
603
Registered
2023-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A190- Acute miliary tuberculosis of a single specified site Health Condition 2: A191- Acute miliary tuberculosis of multiple sites Health Condition 3: A192- Acute miliary tuberculosis, unspecified Health Condition 4: A171- Meningeal tuberculoma Health Condition 5: A199- Miliary tuberculosis, unspecified Health Condition 6: A198- Other miliary tuberculosis Health Condition 7: A158- Other respiratory tuberculosis Health Condition 8: A178- Other tuberculosis of nervous system He

Interventions

None listed

Sponsors

DR TMA PAI PhD FELLOWSHIP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Tuberculosis patients who take anti-tuberculosis drugs and comedications Tuberculosis patients aged 18 and above

Exclusion criteria

Exclusion criteria: Patients with liver abnormalities based on abnormal liver function tests during admission Pregnant and lactating tuberculosis patients Mentally challenged tuberculosis patients

Design outcomes

Primary

MeasureTime frame
Early identification of risk factors and prevention of drug-drug interactions in tuberculosis patients by using a developed prediction model The developed model serves as the point of care for tuberculosis patients Reduction in anti-tuberculosis drugs related liver injuryTimepoint: 24th month

Secondary

MeasureTime frame
The developed model serves as the point of care for tuberculosis patients Reduction in anti-tuberculosis drugs related liver injuryTimepoint: 30th month

Countries

India

Contacts

Public ContactDr Mahadev Rao

Manipal College of Pharmaceutical Sciences

mahadev.rao@manipal.edu8105706060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026